Cargando…

Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices

Detalles Bibliográficos
Autores principales:	Zhou, Anna Y., Trujillo, Jennifer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2018
Materias:	Departments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243215/ https://www.ncbi.nlm.nih.gov/pubmed/30510393 http://dx.doi.org/10.2337/ds17-0048

Ejemplares similares

Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020)

An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
por: Patel, Dhiren
Publicado: (2020)

Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020)

Energy Balance in Hypothalamic Obesity in Response to Treatment with a Once-Weekly GLP-1 Receptor Agonist
por: Shoemaker, Ashley H., et al.
Publicado: (2022)

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
por: Rhinehart, Andrew S.
Publicado: (2015)

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes
por: Di Dalmazi, Giulia, et al.
Publicado: (2022)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016)

InPen Smart Insulin Pen System: Product Review and User Experience
por: Gildon, Bradford W.
Publicado: (2018)

Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy
por: Wiley, Kenneth Calvin, et al.
Publicado: (2015)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Patel, Dhiren
Publicado: (2020)

Managing the multifaceted nature of type 2 diabetes using once‐weekly injectable GLP‐1 receptor agonist therapy
por: Bzowyckyj, Andrew
Publicado: (2020)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Satisfaction and usability of the recombinant chorionic gonadotropin prefilled pen: a survey in Italy
por: Dallagiovanna, Chiara, et al.
Publicado: (2022)

A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents
por: Cornell, Susan
Publicado: (2020)

Gems of Pen Arts
Publicado: (1871)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

Formative usability evaluation of a fixed-dose pen-injector platform device
por: Lange, Jakob, et al.
Publicado: (2018)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Exenatide once weekly: clinical outcomes and patient satisfaction
por: Jose, Biju, et al.
Publicado: (2010)

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Kayaniyil, Sheena, et al.
Publicado: (2016)

A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
por: Webb, Neil, et al.
Publicado: (2018)

Sick and Wounded in Confederate Pens and Prisons
Publicado: (1865)

Smart Connected Insulin Pens, Caps, and Attachments: A Review of the Future of Diabetes Technology
por: Sangave, Nikhil A., et al.
Publicado: (2019)

Potatoes as Pen Wipers
Publicado: (1883)

Capital Punishment: The Slaughter Pen at Sing Sing
Publicado: (1912)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

Usability of the Gla-300 Injection Device Compared With Three Other Commercialized Disposable Insulin Pens: Results of an Interview-Based Survey
por: Klonoff, David, et al.
Publicado: (2015)

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2021)

Dose Accuracy, Injection Force, and Usability Assessment of a New Half-Unit, Prefilled Insulin Pen
por: Kappes, Christopher M., et al.
Publicado: (2017)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

GLP-1 receptor agonists: an updated review of head-to-head clinical studies
por: Trujillo, Jennifer M., et al.
Publicado: (2021)

Usability of devices for self-injection: results of a formative study on a new disposable pen injector
por: Lange, Jakob, et al.
Publicado: (2014)

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)
por: Matza, Louis S., et al.
Publicado: (2019)

Dr. Gardette and His Proposition, Once More
Publicado: (1851)

Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan
por: Sen, Rohini, et al.
Publicado: (2016)

The renoprotective effect of once‐weekly GLP‐1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67)
por: Tsuchida, Ken‐ichi, et al.
Publicado: (2022)

A new pen device for injection of recombinant human growth hormone: a convenience, functionality and usability evaluation study
por: Sauer, Maritta, et al.
Publicado: (2017)

A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin
por: Witkowski, Michal, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_60lo23pfa64scc54fi4uf56ffd